Maxim Group analyst Jason McCarthy maintained a Buy rating on Aprea Therapeutics (APRE – Research Report) yesterday and set a price target of $16.00. The company’s shares closed yesterday at $3.98.
According to TipRanks, McCarthy is an analyst with an average return of -30.7% and a 20.68% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Daré Bioscience, Lineage Therap, and SELLAS Life Sciences Group.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aprea Therapeutics with a $18.00 average price target, representing a 352.27% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
See today’s best-performing stocks on TipRanks >>
APRE market cap is currently $14.85M and has a P/E ratio of -0.59.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.
Read More on APRE:
